Pembrolizumab for first-line mRCC: Anecdotal evidence in real-world setting

Arjun V. Balar, MD, discusses combination treatment with pembrolizumab (Keytruda) and axitinib (Inlyta) in the first-line setting for metastatic RCC.

In this video, Arjun V. Balar, MD, discusses the use of the immune checkpoint inhibitor pembrolizumab (Keytruda) for the treatment of metastatic renal cell carcinoma. Balar is associate professor of medicine at the NYU Grossman School of Medicine and genitourinary medical oncology program director at NYU Langone’s Perlmutter Cancer Center, New York.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.